CytoSorbents(CTSO)

Focus: CytoSorbents is a public biotechnology company specializing in blood purification therapy devices, primarily the CytoSorb hemoadsorption platform for critical care indications. The company operates at mid-cap scale with ~$36M in annual revenue (FY 2025) and is positioned in the niche but growing extracorporeal therapy market.

Gastroenterology Infectious Diseases Cardiovascular

Profile data last refreshed 1h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

Should You Work at CytoSorbents?

AI assessment

CytoSorbents offers focused technology expertise but faces near-term financial stress and shows limited near-term hiring—suitable only for highly mission-driven candidates comfortable with restructuring risk.

Why Work Here

Focused platform play: CytoSorb's single-product-family approach creates deep technical expertise and reduces portfolio dilution risk common in larger biotech

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Mid-stage

2 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$36M

Key Products

CytoSorb

Sepsis, Septic Shock, Cardiac Surgery, Acute Liver Failure (multi-indication platform)

Growth

Flagship hemoadsorption device platform supporting 15+ indication trials and core commercial driver for the company.

Pipeline & Clinical Trials

Help build intelligence for CytoSorbents

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Broad clinical applications: 26 active programs spanning sepsis, cardiac surgery, liver failure, and infectious disease suggest multiple expansion pathways for career impact

Public company stability: NASDAQ-listed (CTSO) with institutional backing reduces early-stage startup failure risk

Watch Out For

Deteriorating cash position: Cash dropped 79% from $14M (FY 2024) to $3M (FY 2025) while net losses remained substantial ($-20.7M FY 2025), signaling runway concerns
No active hiring: 0 open positions and absent H1B sponsorship data suggest organizational contraction or hiring freeze
Clinical execution risk: Majority of pipeline programs lack clear clinical phase designation (marked 'N/A'), and only 2 Phase 3 programs identified despite 26 trials, indicating uncertain development velocity

Generated by Claude from CytoSorbents's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

CytoSorb 300 mL device

COVID-19

N/A

Clinical Trials (1)

NCT04391920Registry of CytoSorb Therapy in COVID-19 ICU Patients

N/A

CytoSorb

Aneurysmal Subarachnoid Haemorrhage

N/A

Clinical Trials (1)

NCT05259514CytoSorb SAH Trial

N/A